Treatment in Calcified Coronary Disease
Conditions
Keywords
Intravascular Lithoplasty, Cutting Balloon, Calcified Coronary Disease, Percutaneous Coronary Intervention
Brief summary
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Detailed description
The trial will be composed of two cohorts: * Patients treated with up-front rotational atherectomy * Patients in whom atherectomy is not planned Randomization to either cutting balloon angioplasty or intravascular lithotripsy will occur as follows in the 2 cohorts: * After rotational atherectomy is safely completed In the rotational atherectomy arm * After safe and successful wire crossing in patients in whom atherectomy is not planned. The trial is designed to demonstrate non-inferiority between cutting balloon angioplasty and intravascular lithotripsy in each cohort with regards to the primary endpoint of post-procedural stent area as measured by intravascular imaging at the site of maximal calcification.
Interventions
Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
DEVICECutting Balloon
Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Sponsors
Baim Institute for Clinical Research
Robert W. Yeh, MD
Ajay Kirtane, MD
C. Michael Gibson, MS, MD
Kathleen Kearney, MD
Akiko Maehara, MD
Suzanne Baron, MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Subject is \> 21 years old 2. Subject with an indication for PCI for the treatment of a) stable coronary artery disease; b) unstable angina; or c) NSTEMI with evidence of down-trending biomarkers 3. Subject is willing and able to provide informed written consent Angiographic Inclusion Criteria 1. The target lesion is a de novo native coronary lesion 2. The target vessel is a native coronary artery with either: 1. A stenosis \> 70%; or, 2. A stenosis \> 50% and \<70% with evidence of ischemia via either positive stress test, FFR value \< 0.80 or RFR/iFR/DFR value \< 0.89 3. The reference diameter of the target vessel is \> 2.5mm and \< 4.0 mm at the lesion site 4. The target lesion has evidence of significant calcium at the lesion site defined either as, 1. The presence of radiopacities involving both sides of the arterial wall \> 5mm and involving the target lesion on angiography 2. the presence of \> 270o arc of superficial calcium on intravascular imaging with a length \> 5mm or the presence of 360o arc of superficial calcium
Exclusion criteria
<!-- --> 1. Patient is pregnant 2. Patient is actively participating in another clinical trial 3. Known LVEF \< 25% 4. Ongoing Non-STEMI with rising biomarkers 5. Cardiogenic shock or requirement for mechanical/pharmacologic hemodynamic support 6. Planned use in the randomized lesion of a bare metal stent or non-stent treatment only 7. Patient has a known allergy to contrast which cannot be adequately pre-treated 8. Patient has a history of bleeding or coagulopathy and is unable to receive blood transfusion if needed 9. Patient presents with STEMI 10. Patient is unable to tolerate dual anti-platelet therapy 11. Patient has suffered a recent cerebrovascular event (stroke/TIA) within last 30 days Angiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Endpoint | 30 days | Post-procedural stent area at the point of maximum calcification as measured by intravascular imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Procedural Cost | Index procedure | — |
| Procedural success | Index procedure | Procedural success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow) with final TIMI 3 flow in the target vessel and the absence of intra-procedural death |
| Angiographic success | Index procedure | Angiographic success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow) |
| Strategy success | Index procedure | Strategy success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g., severe dissection, perforation, abrupt closure or no-reflow and not having to use an alternative calcium modification device (e.g. atherectomy device or specialty balloon other than routine non-compliant balloon) |
| Peri-procedural Myocardial Infarction | within 48 hours of index procedure | Peri-procedural Myocardial Infarction as defined by Academic Research Consortium-2 |
| In-hospital MACCE | hospitalization | In-hospital MACCE defined as composite of all-cause death, unplanned urgent target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at hospital discharge. |
| 30 Day MACCE | 30 days | 30 Day MACCE defined as composite of all-cause death, unplanned target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at 30 days |
Countries
United States
Outcome results
None listed